Posts Tagged ‘Candice Hughes’

Pharma Generosity: Who Donates the Most?

Tuesday, June 29th, 2010

According to the Financial Times, Glaxo donates the most medication to the poor. Merck was in second place and Novartis in third place. The article noted that most Eurpoean companies ranked above their US-based peers. In 11th (last) place was the only Japanese company listed- Daiichi Sanyko.

One advantage cited in the article to donating medications is positioning a company to succeed in emerging markets. As noted earlier this year in BioPharma Pulse, emerging markets are the expected growth areas for the future. Pharma companies may want to consider their overall profile in emerging markets and identify ways to raise their profile. These tactics will likely vary by country as marketing has moved to increased personalization and away from one-sized fits all. Increasing donations may not only raise a company’s profile, but also strengthen the humanity of the donors as well as alleviate suffering.

BioPharma Pulse: New Issue Available Soon

Sunday, June 13th, 2010

The newest issue of BioPharma Pulse will be available next week. Learn about how the healthcare bill will affect pharma’s bottom line, customer communication in a crisis, new pharma/physician guidelines and more.

Subscriptions are available free of charge for qualified Editors, Project Managers/Directors, and others at medical communications, pharmaceutical, or biotech companies. Contact admin at hughesbiopharma.com to see if you qualify today!

Pharmaceutical Drug Sales Outlook Mixed

Wednesday, April 21st, 2010

IMS Health released data today indicating that pharmaceutical drug sales growth will slow globally to between 4% and 6% down from 7% last year. Generic drugs and patent expirations will continue to pressure brand drugs.

However, drug sales globally are expected to be up for 2010, growing 5% worldwide. Much of the growth is expected to come from China and India. One challenge for leading biopharma companies will be the large amount of fake drugs in these countries as well as established generic competitors. Successful branded biopharma products need a solid reputation for safety and superiority if consumers are to be expected to pay substantially more for them.

IMS Health predicts that the top disease therapy growth areas will be: diabetes, cancer, HIV, and multiple sclerosis.

http://bit.ly/Pharma_Forecast_2010

http://bit.ly/Drug_Sales_2010

The Future of Medical Writing: Career Advice

Wednesday, May 13th, 2009

On May 6, I was honored to be a panelist at the AMWA New England Chapter meeting along with Tom Gegeny of Envision Pharma and Michelle Horan of Pfizer. We were asked to discuss three areas of medical writing and answer audience questions on career advice and the future of medical writing in our areas.

The topic was timely given the overall business climate. Nearly 30 people attended, packing the restaurant.

One thing that stood out for me was the overall passion for medical writing. While everyone was a least a bit anxious about the immediate future, no one mentioned changing careers. In fact, several new writers attended hoping to start careers in medical writing. Others were interested in switching from one area of medical writing to another.

I asked Tom (the President-elect of AMWA) about numbers of new members. He told me that AMWA is indeed continuing to grow steadily and there are now nearly 6,000 members. I’ve been observing this upward trend for some years. This trend underscores the fact that medical writing continues to be an attractive career option.

As I’ve always recommended to new medical writers, at the meeting I suggested starting off working at a company (either medical communications or pharmaceutical or other related company) before trying to begin a consulting business. It makes sense to learn the ropes first.

For those already in medical writing or considering starting a career, the more you can network and continue learning about the field, the more successful you will be. This applies to all areas of medical writing. The one point made by all the panelists, and some of the attendees as well, is that medical writing is a constantly changing discipline since the regulations that guide our work are always changing. So you need to keep on top of changes and trends.

To learn more about what was discussed during this productive meeting, look for my upcoming article in the fall AMWA Journal.